Inhibitor of differentiation-1 (Id-1) has been accepted as a putative oncogene to promote oncogenic processes through inactivation of tumor suppressors and activation of growth promoting pathways. Here, we show that Id-1 activates the Akt pathway by inhibition of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) transcription through downregulation of p53. Id-1 negatively regulated both p53 and PTEN at the transcriptional level. In promoter assay with serial deletion and chromatin immunoprecipitation assay, the binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation. This led to Akt phosphorylation at Ser473 and the activation of the Akt-mediated canonical Wnt signaling pathway. The glycogen synthase kinase-3b phosphorylation at Ser9, stabilization and nuclear localization of b-catenin, T-cell factor (TCF)/lymphoid enhancer factor transactivation activity and cyclin D1 expression were enhanced by Id-1. On the other hand, Akt-mediated p27
Introduction
The inhibitor of differentiation (Id) or DNA-binding genes were originally identified in murine myoblasts, where they prevented myogenic basic helix-loop-helix transcription factors from binding muscle-specific regulatory elements (Benezra et al., 1990) . Over the past several years, Id-1 has been thought to be an oncogene, which is overexpressed in various human cancers. Id-1 has been implicated in cell proliferation, survival, invasion, angiogenesis and metastasis (Ling et al., 2006) . Previously, we reported that Id-1 overexpression correlated with tumor angiogenesis in invasive ductal carcinomas (Jang et al., 2006) and Id-1-induced vascular endothelial growth factor by increasing hypoxia-inducible factor-1a stability and activity, and promoted tumor angiogenesis (Kim et al., 2007b) . These diverse functions of Id-1 seem to be partially mediated by the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway. Recently, Li et al. (2007) reported that Id-1 activated the PI3K/Akt/NF-kB pathway, which is implicated in cell proliferation and apoptosis. Furthermore, a recent study showed that Id-1-induced Akt-mediated epithelialmesenchymal transition (EMT) and enhanced cell migration through interacting with caveolin-1 (Cav-1) in prostate cancer (Zhang et al., 2007) . However, the mechanism of Akt activation by Id-1 has not yet been elucidated.
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a dual protein/lipid phosphatase that can dephosphorylate phosphatidylinositol 3,4,5-triphosphate produced by PI3K, is an important tumor suppressor gene in human cancer (Cully et al., 2006) . It is frequently mutated or downregulated in several human cancers and its disruption leads to activation of the Akt pathway (Blanco-Aparicio et al., 2007) . In addition, several studies have shown that PTEN is linked to p53, another crucial tumor suppressor gene. It has been shown that PTEN transcription can be regulated by p53 because the PTEN promoter contains a p53-binding site element that is required for transactivation of PTEN (Stambolic et al., 2001) . Loss of p53 resulted in reduction of PTEN expression and increased ultraviolet-induced Akt activation in mouse epidermal CI41 cells (Wang et al., 2005) . Moreover, PTEN can interact with p53, leading to inhibition of murine double minute 2 (MDM2)-mediated p53 protein degradation by MDM2 (Mayo et al., 2002) .
In this study, we demonstrate how Id-1 activates the PI3K/Akt signaling pathway and affects its downstream effectors, the Wnt/T-cell factor (TCF) pathway and p27
Kip1
. We report here that Id-1 inhibits PTEN transcription by downregulating p53 expression, which induces the PI3K/Akt-mediated Wnt signaling pathway and p27
Kip1 phosphorylation and its cytosolic retention. Therefore, these data suggest that Id-1 is a novel PTEN inhibitor and its inhibition of PTEN could implicate many oncogenic biologic functions of Id-1 such as cell proliferation, tumor invasion and metastasis.
Results
Id-1 regulates the Akt signaling pathway in human breast cancer cells Although Akt activation by Id-1 was recently reported (Li et al., 2007) , the underlying mechanism has not been elucidated. Firstly, we investigated the effect of Id-1 on Akt phosphorylation and its downstream effectors in human breast cancer. As shown in Figure 1a , upon Id-1 overexpression in MCF7 cells, Akt phosphorylation at Ser473 was increased as assessed by immunoblotting. Furthermore, Wnt/TCF pathway-related molecules were significantly changed by Id-1. Glycogen synthase kinase3b (GSK-3b) was inhibited by phosphorylation. In consequence, the expression level of b-catenin and cyclin D1 were upregulated by Id-1. Such effects were specific to Id-1 overexpression, as these changes were reversed by the blockade of Id-1 expression using antisense construct. In addition, p27
Kip1 phosphorylation at Thr157 was enhanced by Id-1 and this effect was inhibited by Id-1 retroviral antisense expression. Consistent with these observations, knockdown of Id-1 in MDA-MB-231 cells led to reductions of Akt, GSK-3b and p27
Kip1 phosphorylations, and b-catenin and cyclin D1 expressions (Figure 1b) . To confirm accurate knockdown of Id-1 expression, not another Id family that have high degree of homology with Id-1, we determined the expression of Id-3 in Id-1 antisense-infected cells by western blot analysis. However, Id-3 expression was undetected in both MCF7 and MDA-MB-231 cell lines (data not shown). As shown in Figure 1c , Id-1-induced activation of Akt and upregulations of its effectors, phospho-GSK-3b, cyclin D1 and phospho-p27
Kip1 at Thr157 were abolished in the treatment with PI3K inhibitor, LY294002 (50 mM) for 6 h. Therefore, these data suggest that Id-1 enhances Akt phosphorylation and regulates Akt downstream signals in human breast cancer cells.
Id-1 inhibits PTEN transcription through p53 downregulation
To reveal more exactly the mechanism of Id-1-induced Akt activation, we further explore the upstream signaling of Akt. Because PTEN can be transactivated by p53 (Stambolic et al., 2001) , and we previously found Figure 2a , both p53 and PTEN protein levels were reduced by Id-1 and these changes were restored by suppression of Id-1 using retroviral antisense construct (left). These mRNA levels were also downregulated by Id-1, suggesting that Id-1 regulated both p53 and PTEN at the transcriptional level ( Figure 2b ). To examine whether Id-1 regulates PTEN transcription through the p53-binding site, the PTEN gene promoter activity with serial deletion was measured. As shown in Figure 2c , the luciferase activities of both pGL3-PTENpro621 (within the À1517 to À897 bp promoter region) and pGL3-PTENpro448 (within the À1344 to À897 bp promoter region) that contain the p53-binding site were reduced by Id-1, whereas the luciferase activity of pGL3-PTENpro65 (within the À961 to À897 bp promoter region), which has no p53-binding site, was low in both control and Id-1 overexpressing MCF7 cells. To confirm the results, the activity of mutant PTEN promoter with altered single nucleotide within p53-binding site was also determined. Its activity was low in the both cells, suggesting that p53 binding to PTEN promoter is very important to PTEN transcription activity. To confirm whether Id-1 actually affects p53 binding to the PTEN promoter region, chromatin immunoprecipitation (ChIP) assay was performed. The binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation ( Figure 2d ). Consistent with these observations, constitutive expression of p53 blocked Id-1-mediated PTEN downregulation ( Figure 2e ). Collectively, these data suggest that Id-1 is a novel PTEN inhibitor and activates the Akt pathway by inhibition of PTEN transcription through downregulation of p53. The cell lysates and total RNA, prepared as in Figure 1a , were subjected to immunoblotting and reverse transcription (RT)-PCR, respectively. (c) Illustration of PTEN promoter reporters used for luciferase assay (top). Cells were transfected with pGL3-basic vector (pGL3-basic), truncated pGL3-PTEN promoters for 48 h or mutated pGL3-PTEN promoter (PTENpro448(^p53)), serum starved for 48 h and then the promoter activity was measured as described in Materials and methods section. (d) Each cell was serum starved for 48 h, and then chromatin immunoprecipitation (ChIP) assay was carried out. The crosslinked, sonicated cell lysates were immunoprecipitated with p53 antibody. After washing, reverse crosslinking and DNA extraction, PCR analysis was carried out using the primers designed in the PTEN promoter region containing the p53-binding site.
(e) Id-1 overexpressing MCF7 cells were transfected with pCI-neo or pCI-neo-p53 for 48 h, serum starved for 48 h, and subjected to immunoblotting. All experiments were performed in triplicate. *Statistically significant difference of Po0.05.
Activation of the Akt-mediated Wnt/TCF pathway by Id-1 overexpression in MCF7 cells A recent study showed that Id-1-induced Akt-mediated EMT and enhanced cell migration (Zhang et al., 2007) . Consistently, our data showed Id-1-induced Akt activation, GSK-3b phosphorylation and b-catenin and cyclin D1 expressions (Figure 1a) . Therefore, we next explored whether Id-1 activated the Wnt/TCF pathway. To investigate whether Id-1-induced b-catenin stabilization led to translocation of b-catenin to the nucleus, we examined the subcellular localization of b-catenin in Id-1 overexpressing MCF7 cells. Both total and nuclear b-catenin expressions were increased by Id-1 and these effects were abolished by LY294002 treatment (Figures 3a and b) . Consistently, accumulation of nuclear b-catenin expression was seen in Id-1 overexpressing MCF7 cells as assessed by immunocytochemistry ( Figure 3c ). Lithium chloride (LiCl), which mimics Wnt signaling by inhibiting GSK-3b activity, was used as a positive control of nuclear b-catenin (van Noort et al., 2002) . To confirm whether Id-1-induced nuclear b-catenin expression activates TCF/lymphoid enhancer factor (LEF) transcription activity, the promoter assay with TCF/ LEF promoter (TCF optimal promoter (TOP)) or its mutant form (fake optimal promoter) containing binding sites for Tcf4 (Korinek et al., 1997) was analysed. As shown in Figure 3d , TCF/LEF promoter activity was increased by Id-1 and strongly decreased upon Id-1 suppression by antisense construct (left). Moreover, in MCF7 cells transiently cotransfected with Id-1 and TOP promoter, Id-1 increased TCF/LEF promoter activity in a dose-dependent manner (lanes 3 and 5), and this activation was also prevented by LY294002 treatment (lane 7; right). Taken together with the results in Figure 1a , these data suggest that Id-1 activates the Akt-mediated Wnt/TCF signaling pathway.
Id-1 induces Akt-mediated p27 phosphorylation and its cytosolic retention As Akt-mediated p27 Kip1 phosphorylation at Thr157 was upregulated by Id-1 (Figure 1) , we next examined whether this change affected inhibition of its nuclear import (Shin et al., 2002) . The subcellular localization of p27 Kip1 was biochemically investigated by immunoblotting using nuclear/cytoplasmic fractional extraction. MCF7 cells showed predominant nuclear p27 Kip1 , whereas p27
Kip1 was localized in both cytosol and the nucleus in Id-1 overexpressing MCF7 cells (Figures 4a and b) . Consistent with this finding, p27
Kip1 was translocated to cytosol upon Id-1 overexpression as assessed by immunocytochemistry (Figure 4c ). Such changes in the localization of p27 Kip1 were reversed by the PI3K inhibitor. Therefore, these data suggest that Id-1 can stimulate cell cycle progression by inhibition of p27 Kip1 function by enhancement of Akt-mediated phosphorylation and cytosolic retention of p27 Kip1 .
Discussion
In this study, we firstly disclose Id-1 as a novel PTEN negative regulator that could be implicated in many biologic oncogenic functions of Id-1 such as cell proliferation, tumor invasion, EMT and metastasis. Our data propose the model for regulation of the Akt pathway by Id-1 (Figure 5 ). Id-1 suppressed p53 expression at the transcriptional level and then inhibited direct binding of p53 to the PTEN promoter region. This led to inhibition of p53-mediated PTEN transactivation. Downregulation of PTEN transcription resulted in activation of the Akt-mediated Wnt/TCF signaling pathway and Akt-mediated p27
Kip1 phosphorylation and its cytosolic retention. These results suggest the novel action of the mechanism of Id-1 through the PTEN/Akt pathway in human breast carcinogenesis.
Id-1 activates the PI3K/Akt/NF-kB pathway that is implicated in cell proliferation and survival to anticancer drug (Li et al., 2007) . Recently, it was reported that Id-1 inhibits protein phosphatase 2A activity, which led to Akt dephosphorylation (Zhang et al., 2007) . Here, our data provide the first evidence that Id-1 can control PTEN as a novel negative regulator that activates the Akt pathway. The PTEN gene transcription is regulated by diverse transcriptional factors. C-Jun binds to the AP-1 site of the PTEN promoter and can suppress its transcription, whereas Egr-1 activates PTEN transcription by direct binding to the PTEN 5 0 untranslated region (Virolle et al., 2001 ). In addition, p53 has been reported as a crucial PTEN transactivator (Stambolic et al., 2001) . It was also reported that suppression of p53 mutant expression is involved in upregulation of p21 and PTEN (Vikhanskaya et al., 2007) . Therefore, it has been suggested that p53 expression level and its mutation status may be important to PTEN regulation. Id-1 seems to regulate many biological effects by p53 modulation. Recently, we showed that Id-1 regulates both bcl-2 and bax expressions through inhibition of p53 expression and has a protective effect on taxol-induced apoptosis (Kim et al., 2007a) . Here, we also demonstrate that Id-1 inhibited PTEN expression and activated the Akt pathway through p53 regulation. Therefore, it may be suggested that both p53 and PTEN are crucial mediators of Id-1-induced oncogenesis and activation of Id-1 could be effective for loss of the functions of these tumor suppressor genes.
EMT has been proposed as a crucial step for progression of invasion and metastasis in human cancer. Tumor invasion and EMT are associated with Wnt activation by regulating the b-catenin/E-cadherin complex (Nelson and Nusse, 2004) . Moreover, the b-catenin/TCF complex that is induced by the canonical Wnt pathway enhanced the Axin2-dependent pathway and increased stabilization of Snail, a critical regulator of EMT (Yook et al., 2006) . Id-1 is also involved in tumor angiogenesis and invasion/ metastasis (Ling et al., 2006) . Recently, it has been reported that the interaction of Id-1 with Cav-1 resulted in suppression of epithelial marker expression, enhancement of mesenchymal marker expression and cell migration (Zhang et al., 2007) . Here we found that Id-1 activated the Akt-mediated Wnt/TCF signaling pathway through PTEN inhibition, suggesting that Id-1 is implicated in tumor invasion and progression through the PTEN/Akt pathway and could be an important part of the modulation of EMT.
Accumulating evidence has shown that Id-1 induces cell proliferation through the alteration of cell cycle regulators including inactivation of the p16 containing Tcf4-binding sites (TCF optimal promoter (TOP)) or its mutant form (fake optimal promoter (FOP)) for 48 h, serum starved for 48 h and then promoter assay was carried out (left). MCF7 cells were cotransfected with pCI-neo-Id-1 plasmid ( þ and þ þ , 1 and 5 mg of DNA, respectively) and TOP or FOP plasmids, and/or treated with 50 mM LY294002 for 24 h, and then luciferase activities were measured (right). As a positive control, the TCF/LEF promoter activity was measured in cotransfected cells with b-catenin expression vectors. The above results are shown as mean values with ±s.d. of triplicate determinations. * and w Statistically significant difference of Po0.05 compared with pCI-neo vector and pCI-neo-Id-1, respectively. E in several human cancers. In human breast epithelial cells, Id-1 enhances cyclin D1 and cyclin E expressions and affects CDK4 and CDK2 activities (Swarbrick et al., 2005) . We have previously reported the enhancement of cell growth and induction of G 1 to S phase transition by ectopic Id-1 expression in MCF7 breast cancer cells (Kim et al., 2007a) . In this study, our data show that Id-1 enhances the Akt-mediated Wnt/TCF pathway and cyclin D1 expression, a TCF/LEF response gene, and leads to Akt-mediated p27 Kip1 phosphorylation and its cytosolic retention in MCF7 breast cancer cells. Therefore, our data provide that Id-1 could regulate p27 Kip1 and cyclin D1 by the Akt pathway and suggest that both cyclin D1 and p27
Kip1 are important regulators in controlling cell cycle progression of G 1 to S phase transition in Id-1-induced cell proliferation.
In summary, our data suggest Id-1 as a novel negative regulator of PTEN that activates the PI3K/Akt signaling pathway and its downstream effectors, the Wnt/TCF pathway and p27
Kip1 phosphorylation. These findings suggest that the PTEN/Akt pathway could participate in many biological effects of the Id-1 oncogenic function such as cell proliferation, invasion and metastasis, supporting the finding that Id-1 has been involved in the progressive and aggressive phenotype of human breast cancer. (sc-488), , cyclin D1 (sc-718), p27
Materials and methods

Chemicals and antibodies
Kip1 (sc-528), Sp1 (sc-420) and PTEN (sc-7974) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); phospho-Akt (9276), total Akt (9272), phospho-extracellular signal-regulated kinase (ERK), phospho-GSK-3b (9336) and total GSK-3b (9315) Cell culture and establishment of stably Id-1 transfected pool MCF7 cells MCF7 cells were grown in RPMI 1640 medium (WelGene, Daegu, South Korea) supplemented with 10% fetal bovine serum (WelGene). MCF7 cells stably expressing empty vector (pCI-neo) or pCI-neo-Id-1-HA were generated as previously described (Kim et al., 2007b) , and maintained in RPMI 1640 medium containing 100 mg/ml G418 (Sigma).
Western blot analysis
Cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate) supplemented with protease inhibitors (Complete, Mini, EDTA-free; Roche Applied Science, Penzberg, Germany), phosphatase inhibitor cocktails 1 and 2 (Sigma) and immunoblotting was carried out as described (Yoo et al., 2003) . The immunoblotting band densities were measured using AlphaEase FC software (Alpha Innotech Inc., San Leandro, CA, USA).
RT-PCR
Total RNA isolation and reverse transcription (RT)-PCR were performed as previously described (Kim et al., 2007b) . The following primers were used: PTEN, 5 0 -TCTCCAAATT TTAAGGTGAAGC-3 0 and 5 0 -ATGCTGATCTTCATCAAA AGGT-3 0 ; p53 and glyceraldehyde-3-phosphate dehydrogenase primers have been described previously (Kim et al., 2007b) . The RT-PCR band densities were determined as above.
Promoter assay PTEN promoter constructs including a 621-bp genomic fragment corresponding to the region of the PTEN promoter between bases À1517 and À897 (pGL3-PTENpro621), a 448-bp fragment containing bases À1344 to À897 (pGL3-PTENpro448) and its mutant with p53-binding site and a 65-bp fragment containing bases À961 to À897 (pGL3-PTENpro65) were generated as previously described (Chung et al., 2003) . Transfection of plasmid DNA into cells was performed using Moreover, the Akt phosphorylation inhibits p27 Kip1 function through its phosphorylation and nuclear import inhibition. Therefore, Id-1 may be involved in many Akt-mediated biological effects such as cell proliferation and epithelial-mesenchymal transition (EMT) through PTEN inhibition.
transfected with reporter and expression plasmids as indicated. To correct the variance of transformation efficiency in each assay, a pCMV-b-gal was co-introduced. The cells were then harvested and lysed and luciferase activities were determined using a Microplate Luminometer (Berthold, Oak Ridge, TN, USA). Luciferase activity, corrected for b-galactosidase activity in each corresponding cell lysate, was expressed as relative units.
ChIP assay
ChIP assay was carried out using a ChIP assay kit (Upstate Biotechnology) following the manufacturer's instructions. The following primers were used: PTEN promoter, 5 0 -CAAAAGCC GCAGCAAGTG-3 0 and 5 0 -GAGCGCAGAGTCCCCAAG-3 0 . PCR was carried out using the GeneAmp PCR System (PerkinElmer, Waltham, MA, USA) under the following conditions: 94 1C for 5min, 35 cycles of 941C for 30 s, 60 1C for 30 s, 72 1C for 30 s and then 72 1C for 10 min.
Immunocytochemistry
Cells were seeded onto a four-chamber slide glass (Lab-Tek II Chamber Slide System; Nalge Nunc International, Rochester, NY). The next day, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 in phosphatebuffered saline for 5 min and incubated with 3% bovine serum albumin for 1 h. After the blocking, cells were stained with anti-p27 Kip1 (1:200) or anti-b-catenin (1:500) at 4 1C for 16 h and further reacted with antirabbit immunoglobulin/R-phycoerythrin (1:200; Sigma) for 1 h and 4 0 ,6-diamidino-2-phenylindole dihydrochloride for 10 min. Immunofluorescence was detected by fluorescence microscopy (Nikon, Naka, Japan).
Cell fractionation
Cytosolic and nuclear extracts were prepared according to the manufacturer's protocol using the NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL, USA). The extracts were analysed by immunoblotting as above or stored at À80 1C until use.
Statistical analysis
The statistical analyses were carried out by the Student's t-test using SPSS software (version 11.0; SPSS Inc., Chicago, IL, USA).
